BRAF and neoplasm: In February 2024, Lifileucel (Amtagvi), an autologous tumor-infiltrating lymphocyte (TIL) therapy, received FDA accelerated approval for adults with unresectable or metastatic melanoma who progressed following PD-1 inhibitor therapy—and, if harboring a BRAF V600 mutation, after BRAF ± MEK inhibitors [139].